deltatrials
Terminated PHASE1 NCT00593008

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

A Phase 1 Study of Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Sponsor: Brigham and Women's Hospital

Conditions Pancreatic Adenocarcinoma
Interventions Gemcitabine Temsirolimus
Updated 6 times since 2017 Last updated: Dec 1, 2011 Started: Oct 31, 2007 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

A PHASE1 clinical study on Pancreatic Adenocarcinoma, this trial is terminated or withdrawn. The trial is conducted by Brigham and Women's Hospital and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States